The biopharmaceutical company's stock closed Friday's session at 27.44 euros, down 4.19% from the previous day's close of 28.64 euros. This decline occurred in a deteriorating market context, with the CAC 40 losing 1.53%, but it primarily marks a technical pause after a spectacular rise. Over the past seven days, the stock still shows a gain of 6.52%, while its quarterly performance has reached 72.58%, indicating a particularly strong upward momentum since the summer. Trading volumes remained moderate with 0.71% of the capital traded, reflecting relatively subdued activity for a downturn session.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Technical analysis reveals a clear overbought situation, with the relative strength index reaching a level of 97, well above the critical threshold of 70 that usually signals overheating. This indicator, which measures the speed and magnitude of price changes, suggests that the recent rise has been particularly rapid and that the stock may need a consolidation phase. The price is now significantly above its 50-day and 200-day moving averages, which are at 19.60 euros and 16.47 euros respectively, confirming the strength of the underlying trend. The Bollinger Bands, which frame fluctuations between 17.91 euros and 28.94 euros, show that the stock is currently testing the upper boundary, after having reached its Thursday high at 28.88 euros, a level that also corresponds to its technical resistance.
The recent regulatory approval obtained at the end of September in Canada for LONGAVO, an injectable treatment developed in partnership with Teva, has supported the stock's progression in recent weeks. This risperidone-based medication is now also marketed in the American and South Korean markets. Concurrently, the consensus among financial analysts following the stock displays a median price target of 25.99 euros, indicating a potential downside of 9.27% from the current closing level, suggesting that the recent valuation might have anticipated the short-term prospects. Seven analysts maintain a buy recommendation on the stock, with no negative opinions recorded.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
